With the Technical Assistance ofPhillys Shellady, Linda Rath and Marcia Miller SUMMARY Sixteen acromegalic patients underwent echocardiography, phonocardiography, stress electrocardiography with Thallium perfusion scanning and gated radioisotope left ventricular angiocardiograms. Abnormalities consisting of increased echo left ventricular mass index, low velocity of circumferential fiber shortening or elevated pre-ejection period to left ventricular ejection time ratio were found in six patients with coexistent hypertension or coronary disease. Concentric left ventricular hypertrophy was also found in three patients with no known etiology other than acromegaly of greater than thirteen years' duration or with fasting growth hormone CARDIAC HYPERTROPHY and congestive heart failure have been described in as many as one-third of acromegaly patients.' This has been attributed to coexistent hypertension 2A, 68 which is found in 2342% of acromegaly patients, or to coronary disease.3' However, sporadic reports have described patients who, in the absence of hypertension or coronary disease, have cardiac hypertrophy and diminished ventricular function.1 2, I These reports suggest concentrations greater than 100 ng/ml. One of these three also had left ventricular dysfunction. Neither hypertrophy nor ventricular dysfunction was found in other acromegalics with shorter duration of disease or lower growth hormone concentrations, or with normal growth hormone concentrations after therapy.
A high prevalence of coronary artery and hypertensive heart disease is associated with acromegaly. A few patients with acromegaly have a specific, potentially reversible cardiomyopathy probably related to prolonged acromegaly or very high growth hormone concentrations.
that cardiac abnormalities may be produced as an effect of elevated growth hormone concentration. The purpose of this study was to determine whether a specific acromegalic heart disease could be detected using recently developed noninvasive methods for assessing cardiac size and function.
Methods

Patients
All patients with documented acromegaly by clinical criteria and elevated growth hormone concentration followed by the Endocrinology Division of the University of Iowa Hospital were invited to participate in this study. Of 30 contacted, 22 who responded were admitted to the Clinical Research Center for study. Informed consent was obtained using a format approved by the Committee on Research In-volving Human Beings and the Human Use Subcommittee of the Radiation Protection Committee of the University of Iowa Hospital. Of the patients initially evaluated, 16 had technically adequate echocardiographic (echo) studies and form the basis of this report. Control subjects for the echo and phonocardiographic studies were normal hospital employees and patients found to be normal by cardiac catheterization and coronary arteriography (performed for evaluation of atypical chest pain). Age of controls ranged from 30-67 years with a mean of 48.5 years.
The clinical characteristics of the patients are listed in table 1. Patients were divided into groups I and II according to normal or elevated serum growth hormone (GH) concentrations, respectively, at the time of the study. All group I patients had had elevated GH concentration prior to treatment. Group III patients were separated from these regardless of their GH level because they had angina pectoris, hypertension, or, in one patient, systemic lupus erythematosis, all of which are potentially associated with ventricular hypertrophy or dysfunction. In this group the contribution of elevated GH alone to the observed cardiac abnormalities could not be evaluated. Hypertension was defined as average blood pressure greater than 140/90 even if pressures at the time of the study were normal on therapy.
Endocrine Studies
Serum growth hormone concentrations were measured during a standard 100 g glucose tolerance test. GH was measured by radioimmunoassay using reagents supplied by the National Pituitary Agency.'0 All patients had periodic endocrine evaluation and were taking appropriate hormone replacement therapy when indicated (table 1).
Echo Studies
Complete echo studies were obtained on all patients using a Smith-Kline Ekoline, Model 20A ultrasonoscope employing a 2.25 MHz transducer focused at 7.5 cm and recorded on a Honeywell Model 1856 fiberoptic strip chart recorder. Patients were examined supine or in a partial left lateral decubitus position, whichever best identified cardiac structures. The standard echo position" employing an M-mode sweep was used to identify the septum and posterior wall of the left ventricle (LV) just below the mitral valve for wall thickness and left ventricular function measurements ( fig. 1 ). In addition a minor sweep'2 was done in order to identify the largest end-diastolic dimension (EDD) taken at the R wave of the QRS complex of a simultaneous electrocardiogram (ECG) tracing. End-diastolic posterior wall (LVPW) thickness was measured at the R wave at the chordal level; using these measurements left ventricular mass (LVM) was calculated'3 by the formula: LVM = 1.05 [(LVPW + EDD)3 -(EDD)3] and normalized for body surface area.
We also used the method of Devereux and Reichek'4 to calculate LVM; this method utilizes a slightly different echo measurement convention and a different formula validated by autopsy studies. However, the results obtained by this method were similar to those from the formula of Troy and Pombo,'3 and will not be further discussed. For calculation of the septum to posterior wall thickness ratio, measurements of these structures were taken at the chordal level and posterior mitral leaflet, respectively, of the Mmode sweep at the onset of the P wave of the ECG.1"
In order to quantify LV function, end-systolic dimension was measured at the smallest vertical internal distance during end systole of the same complex in which end-diastolic dimension was measured. Then mean velocity of circumferential fiber shortening (VCF) was calculated by employing a simultaneously recorded carotid pulse tracing to measure LV ejection time.'6 The paper speed was increased to 100 mm/sec to increase the accuracy of this LV ejection time measurement.
Since LV function may be normal at rest, but abnormal under stress, we administered atropine and phenylephrine to both patients and controls.'6 Atropine 1.5 mg by bolus was given to increase heart rate 30 beats/minute and blunt the bradycardia response to phenylephrine. The expected VCF response would be a slight increase.'6 An echo recording was repeated when heart rate was stable for 10 minutes. A constant infusion of phenylephrine was then started (usual dose 40-80 ,ug/min) to raise systolic blood pressure 40 mm Hg over resting systolic blood pressure and the echo was repeated. The expected response is a modest decrease of VCF below the resting value. 16 Seven patients did not receive atropine or phenylephrine. In group II patients, this was because two patients had echo measurements which were difficult to obtain and patient 9 had an abnormal resting value. In group III, one patient did not have an easily obtainable echo and the three remaining had either angina or hypertension. In the latter atropine and phenylephrine were considered potentially hazardous.
Phonocardiographic Studies
As another noninvasive measure of overall LV performance, pre-ejection period to LV ejection time ratios (PEP/LVET) were calculated from simultaneous ECG, phonocardiogram and carotid pulse tracings17 on all patients. Recordings were obtained using a paper-ink Elema-Schonander mingograph -Model EMrecorder at a paper speed of 100 mm/sec. Patients were examined between 8:00 and 10:00 a.m., fasting, in a quiet room familiar to them which was free of distraction.
Cardiac Imaging Studies
In order to detect asynergy, gated radionuclide LV angiograms'6 were done on eleven patients in the supine position after injection of 20 mCi of Technetium9m labeled human serum albumin. Images were obtained with a Picker model 412 scintillation camera in 30°right anterior oblique (RAO) and 450 left anterior oblique (LAO) projections. Enddiastolic and end-systolic images were summations of 200-400 cycles gated on the ECG R wave and terminal T wave, respectively, during expiration using a physiological synchronizer (Brattle Instrument Corporation). The count density was 1500 counts/cm.2 End-diastolic and end-systolic LV outlines were traced and compared by visual inspection for areas of asynergy.1' Although gated scans were abnormal in three of eleven studies performed, in no case was the diagnosis of co-existing heart disease dependent on this test alone.
To assess the presence of coronary disease exercise Thallium-201 perfusion scans20 were done on twelve patients. A multistage, graded treadmill ECG stress test was carried out to symptoms, 100% maximal heart rate, or fatigue.2' An ischemic response was defined as 1 mm STsegment depression 80 msec after the J point. When peak heart rate was achieved 2 mCi of Thallium-201 was injected and exercise was continued at reduced treadmill speed and grade for two additional minutes. After a ten minute rest period, which allowed the ECG to return to normal, scintigrams were performed in 30°RAO, anterior, 45°LAO and left lateral positions, each with an information count density of 2000 counts/cm.2 A definite perfusion defect was read if 20% of the circumference of the ventricle showed diminished or lack of uptake in one view. To search for asymmetrical septal hypertrophy, septum to posterior wall thickness ratios were calculated from the LAO scan as previously described. 22 The scans were read by three separate observers and considered positive or negative when complete agreement could be reached. Thallium perfusion scans were not done in four patients because of unavailability of the isotope during their hospitalization.
Results
Heart size Table 2 shows estimated duration of acromegaly, GH level at the time of the study, and various measurements of heart size.
Group I patients had no abnormalities of any heart size parameter. None of the group II patients had abnormalities of ECG (left ventricular hypertrophy by Estes' criteria23) or chest X-ray (cardiothoracic ratio > 0.50). However, three patients did have significant echo EDD, LVPW and LV mass index abnormalities indicating ventricular hypertrophy (table 2, fig. 2 ). All three had either very high GH Abbreviations: Lowest = lowest growth hormone concentration in response to standard oral glucose tolerance testing; EDD = echocardiographic enddiastolic dimension; ND = not done; LVM index = left ventricular mass index; MNO = measurement not obtainable from echo; IVCD intraventricular conduction defect; LA disease = left atrial disease. levels at the time of study or acromegaly for 13 years or more. Patient 10 had increased LVPW thickness which may be normal at age 66.24
In group III only patients 11 and 15 had normal size measurements; their GH levels were either normal (patient 15) or mildly elevated (patient 11) and their blood pressures had been controlled in a normal range for several years. The four remaining all had abnormal echo parameters indicating left ventricular hypertrophy not detected by ECG or chest X-ray.
LV Function Studies Correlated with Indices of
Coronary Disease
All group I patients had normal LV function studies including VCF response to atropine and phenylephrine (table  3 ). An unexpected finding of a positive exercise Thallium-201 perfusion scan in patient 3 indicates either silent coronary obstruction, spasm25 or, less likely, a false-positive test. In any case this patient's acromegaly is not now associated with LV hypertrophy or dysfunction.
In group II patients whose LV size was normal (including patient 10), LV function studies were also normal at rest and during stress (table 3) . Of the three with increased LVM index, only patient 9 had both an abnormal PEP/LVET ratio compared to eighteen normals ( fig. 3 ) and an abnormally low resting VCF compared to nine normals (table 3) . Exercise tests did not show ischemia and the exercise Thallium-201 perfusion scans in patients 7 and 9 and gated radioisotope LV angiograms in patients 5 and 9 revealed no perfusion or motion defects. A Thallium-201 perfusion scan was not done on patient 5 because of her age. Thus, of the three patients with ventricular hypertrophy not secondary to hypertension or coronary disease26 one had asymptomatic abnormalities of LV function. Ventricular function testing on group III patients confirmed the presupposition of cardiac abnormalities in all except patient 15. Of special note is patient 12 whose resting PEP/LVET and VCF were normal, but whose response to phenylephrine was markedly abnormal (table 3) . Perfusion defects indicating myocardial ischemia or fibrosis were found in all of these patients, even in patients 11 and 15 who had no clinical evidence of coronary disease. This helps to explain the discrepancy between normal echo and abnormal PEP/LVET ratios in patients 11, 13 and 16 since regional motion abnormalities may not be recorded by the echo, but will result in an abnormal PEP/LVET ratio if overall ventricular function is impaired.
Discussion
Previous studies based on clinical criteria, ECG, chest X-ray or death certificate diagnosis document the frequency of ventricular hypertrophy in acromegaly. However, the etiology of this hypertrophy was not clearly delineated and Systolic Time Intervals .'U0
x.x NL GP GP FIGURE 3. Pre-ejection period to left ventricular ejection time ratios. One patient of group II has a PEPIL VET ratio which exceeds any of the normal group; this patient also had a high left ventricular mass index. many patients could have had coexisting diseases. Sporadic patients who have been studied with more sensitive methods such as cardiac catheterization9 and autopsy" 2, 8 have been proven to have hypertrophy in the absence of evidence of coronary or valvular disease. Our study confirms the prevalence of coexisting heart disease in acromegaly; 10 of 16 patients had some identifiable cardiac abnormality. In agreement with previous studies, hypertension was present in 25% and obstructive coronary disease inferred from defects on Thallium-201 scintigrams was present in 38% of our acromegalic patients. There were seven patients (group II) who had elevated growth hormone concentrations, no history of hypertension or coronary disease and no clinical evidence of cardiac disease. We demonstrated ventricular hypertrophy and minimal cardiac dysfunction in one of these patients and left ventricular hypertrophy in two others. Since in acromegaly there is generalized visceromegaly, it is somewhat surprising that cardiac enlargement was not detected in all patients of this group. The three patients with ventricular hypertrophy in this group had either very high or prolonged elevations of growth hormone levels. This is consistent with the data from deGrandpre and Raab's"7 experiments which suggest that very high doses of growth hormone are required to induce ventricular hypertrophy.
Cardiac disease is a frequent cause of death in acromegalyl" 4 and is probably multifactorial in origin. In view of this, particular efforts should be made to eliminate factors such as hypertension which may produce cardiac damage in acromegalic patients. Our data suggest that prolonged high concentration of growth hormone is another etiologic factor which causes left ventricular hypertrophy and may eventually cause cardiac failure. Many experimental studies suggest that cardiac hypertrophy induced by various stimuli will ultimately lead to cardiac failure.28' 29 Furthermore, in many circumstances, removal of the stimulus that induced the ventricular hypertrophy will lead to its regression. 30, 31 This hypothesis is in part supported by the data obtained in this study. None of the acromegalic patients that we studied who had normal growth hormone levels as a result of therapy (group I) had either cardiac enlargement or dysfunction.
Contrary to a recent report," acromegaly was not found to be associated with the syndrome of asymmetric septal hypertrophy (ASH)." Two patients had borderline echo septum to posterior wall thickness ratios (1.3 and 1.4) without evidence of systolic anterior motion of the mitral valve.12 Thallium-201 perfusion scans did not confirm diagnostic septum to posterior wall thickness ratios greater than 1.7, which has been reported in ASH,21 and no clinical correlates of the syndrome, such as arrhythmias, syncope or family history of syncope or sudden death were present.
This study suggests that subclinical cardiac dysfunction, so-called acromegalic cardiomyopathy, is uncommon among asymptomatic patients with acromegaly. However, echocardiographic evaluation of cardiac size is a valuable means of demonstrating left ventricular hypertrophy secondary to growth hormone excess which appears to occur in some patients with acromegaly. The presence of cardiac hypertrophy and/or dysfunction is probably an indication for aggressive therapy designed to normalize growth hormone concentrations and thereby cause a regression of the cardiac abnormalities induced by growth hormone excess.
